NEWTON, Mass.--(BUSINESS WIRE)--Pro-Pharmaceuticals, Inc. (OTCBB: PRWP), the leading developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today named Dr. Peter G. Traber, acting Chief Medical Officer, to lead the FDA Phase III colorectal cancer trial for DAVANAT® as well as the overall FDA approval process. Dr. Traber is a respected researcher, medical and clinical expert, and serves on the Company’s Board of Directors.
